Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Western University of Health Sciences
• Collaborator: American College of Clinical Pharmacy
• Treatments: Natriuretic Peptide, Brain; Nitroglycerin

Criteria

Inclusion Criteria:

• At least 18 years of age.

• Subject must be able to understand the potential risks and benefits associated with the study.

• Baseline systolic blood pressure ≥ 90 mm Hg at the time of enrollment.

• Clinical symptoms of dyspnea and laboratory admission BNP levels > 500 pg/mL.

• Neither pregnant or breastfeeding at the time of enrollment.

• Authorization of patient's enrollment by patient's medical provider.

Exclusion Criteria:

• <18 years of age

• Denies written informed consent

• Pregnant or lactating.

• Baseline systolic BP < 90 mmHg or cardiogenic shock

• No symptoms of congestion or admission BNP < 500 pg/mL

• Known allergy to E.coli-derived products, or any history of anaphylactic reactions to nesiritide.

• Receiving dialysis at the time of enrollment.

• Serum creatinine > 2.5 mg/dL at the time of enrollment.